生产企业：Foresee Pharmaceuticals
FP-045 (mirivadelgat) is a highly selective oral small molecule allosteric activator of ALDH2, developed by Foresee Pharmaceuticals. It is being investigated in Phase 2 clinical trials for Parkinson's disease (SLEIPNIR platform trial) and pulmonary hypertension-interstitial lung disease (WINDWARD study).
FP-045 (mirivadelgat) is a highly selective oral small molecule allosteric activator of ALDH2, developed by Foresee Pharmaceuticals. It is being investigated in Phase 2 clinical trials for Parkinson's disease (SLEIPNIR platform trial) and pulmonary hypertension-interstitial lung disease (WINDWARD study).
Mirivadelgat (FP-045) is a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme. It is designed to increase the activity of ALDH2, which directly clears toxic aldehydes from the brain. By supporting this natural defense system, mirivadelgat accelerates detoxification and could potentially slow the ongoing loss of nerve cells in neurodegenerative diseases such as Parkinson's disease.
Parkinson's disease: Phase 2a (SLEIPNIR platform trial, 40 participants, 12-week treatment, in collaboration with Haukeland University Hospital, funded by Cure Parkinson's). Pulmonary hypertension-interstitial lung disease (PH-ILD): Phase 2 (WINDWARD study, initiated Q2 2025).
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
